TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02060864

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AN-PEP
Description: Two pills are consumed in the morning with a breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AN-PEP
Description: Two pills are consumed in the morning with a breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01839305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Description: Hydrotherapy, monitored by physical therapists, performed in groups of up to 10 volunteers, for 45 min per session, twice a week, for 16 weeks
Study: NCT00701844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing A (Experimental informative writing)
Description: Experimental informative writing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing B (Experimental noninformative writing)
Description: Experimental noninformative writing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Writing C (Control informative writing)
Description: Control informative writing

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Writing D (Control noninformative writing)
Description: Control noninformative writing
Study: NCT01804153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose-derived expanded stem cells
Description: Intralesional application ASC
Study: NCT01910220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033 (SAR391786)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033 (SAR391786)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01436864

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human VEGF Receptor-Fc Fusion Protein
Description: Intravitreal injection of KH902 once per month

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Recombinant Human VEGF Receptor-Fc Fusion Protein
Description: Intravitreal injection of KH902 once per month
Study: NCT01207115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-652
Description: ABT-652 capsules - twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-652
Description: ABT-652 capsules - twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules - twice daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen capsules - twice daily for 8 weeks
Study: NCT03077386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENCOMPASS Intervention
Description: Patients will be matched to a CHN who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (i.e., social, financial, insurance), helping patients set health related goals, liaising with a patient's employer, facilitating health care referrals and appointments, monitoring appointments, and facilitating transportation to appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in person or over the telephone using motivational interviewing principles
Study: NCT03412006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulacimstat (BAY1142524)
Description: 25 mg BAY1142524 are given twice daily over a treatment period of 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets are given twice daily over a treatment period of 6 months
Study: NCT04214405

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fixation of tripodal zygomatic fractures
Description: One point versus two point fixation of tripodal zygomatic fractures
Study: NCT00441155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib, Imatinib
Description: Nilotinib 50 mg and 200 mg gelatin capsules and Imatinib 100 mg and 400 mg film-coated tablets in bottles.. Medication labels for each study drug complied with the legal requirements of each country, were printed in the local language.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib, Imatinib
Description: Nilotinib 50 mg and 200 mg gelatin capsules and Imatinib 100 mg and 400 mg film-coated tablets in bottles.. Medication labels for each study drug complied with the legal requirements of each country, were printed in the local language.
Study: NCT01538849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: 1 tablet = Esomeprazole 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 A mg
Description: 1 tablet = YH4808 A mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 B mg
Description: 1 tablet = YH4808 B mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 B mg
Description: 1 tablet = YH4808 B mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 C mg
Description: YH4808 C mg = 2 x YH4808 B mg
Study: NCT00047229

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study: NCT01994473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: SEP-36385625 as a single oral dose of 10, 25, 50, and 100 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral dose placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856 Open Label
Description: 75 mg SEP-363856 given once-daily
Study: NCT01892800

Intervention type: PROCEDURE
Intervention: Lung resection
Study: NCT02867202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrauterine balloon
Description: After the completion of hysteroscopic adhesiolysis, intrauterine balloon was inserted and inflated with 3-5 mL normal saline which was removed after 1 week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrauterine Contraceptive Device Plus Foley Catheter
Description: After the completion of hysteroscopic adhesiolysis, Intrauterine Contraceptive Device Plus Foley Catheter were inserted into the uterine cavity. Foley Catheter was removed after three days and Intrauterine Device was removed at the second time of hysteroscopy.
Study: NCT03835065

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed Reduction
Description: The primary goal of closed reduction is to maintain appropriate bony alignment and angulation to allow for appropriate healing.
Study: NCT01257412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 5mg Oral dose od
Study: NCT03835065

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closed Reduction
Description: The primary goal of closed reduction is to maintain appropriate bony alignment and angulation to allow for appropriate healing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Long Arm Fiberglass Cast
Description: A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be extended to the shoulder joint if the patient is assigned to the long arm cast group. The mold will then be applied and cast construct will be bivalved and taped.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Arm Fiberglass Cast
Description: A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be complete at this point if the patient is assigned to the short arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
Study: NCT03274752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine (Deroxat) will be administered in a dosage of 20mg q.d. per os continuously for 12 weeks after primary PCI. In week 13, Paroxetine (Deroxat) will be administered in a dosage of 10mg q.d. per os.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo will be given q.d. per os continuously for 12 weeks after primary PCI. In addition, a placebo will be given q.d. per os in week 13 as well.
Study: NCT04129840

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dual combination
Description: Participants will be started on a dual therapy with half dose of CCB and an ARB. If needed, a) the dose of the CCB will be increased at 4 weeks, and b) the dose of the ARB at 8 weeks, if blood pressure remains uncontrolled ((if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP \</=130/80mmHg in patients \<65years and \</=140/90mmHg in patients \>65years)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: triple combination
Description: Participants will be started with low dose (1/4) triple combination treatment with CCB, TZD and ARB. If uncontrolled after 4 weeks, dosages of all drugs will be doubled. If after 8 weeks still uncontrolled dosage will be increased to full dose of all three drugs ((if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP \</=130/80mmHg in patients \<65years and \</=140/90mmHg in patients \>65years)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Participants will be started on regular dose of CCB with a) addition of TZD at 4 weeks, if needed, b) increase of dose of TZD after 8 weeks, if needed (if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP \</=130/80mmHg in patients \<65years and \</=140/90mmHg in patients \>65years)
Study: NCT02859688

Intervention type: GENETIC
Intervention: pyrosequencing

Intervention type: GENETIC
Intervention: pyrosequencing

Intervention type: GENETIC
Intervention: pyrosequencing

Intervention type: GENETIC
Intervention: Methylome

Intervention type: GENETIC
Intervention: Methylome

Intervention type: GENETIC
Intervention: Methylome
Study: NCT01358578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab (AIN457)
Description: secukinumab (AIN457) 150mg or 300mg subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab (AIN457)
Description: secukinumab (AIN457) 150mg or 300mg subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab (AIN457)
Description: secukinumab (AIN457) 150mg or 300mg subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab (AIN457)
Description: secukinumab (AIN457) 150mg or 300mg subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: etanercept 50mg subcutaneous
Study: NCT01555918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole (IV)
Description: intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole (IV)
Description: intravenous (IV)
Study: NCT03984968

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells infusion combined with feeding T cells (FTCs)
Description: Phase1 study Optimal biological doses of feeding T cells identification CAR-T cells infusion combined with FTCs will be given in Philadelphia chromosome positive B-ALL patients with remission. FTCs will be administered at the dose of 5×106/kg, 3.25×106/kg or 2×106/kg two hours after ssCART-19 infusion on day 1 and once again administered at the same dose on day 8.~Phase 2 Expansion Study CAR-T cells infusion combined with FTCs at optimal biological dosage determined in Phase 1 study will be given in expanded Philadelphia chromosome positive B-ALL patients with remission. Bayesian optimal design is applied in this Phase 2 study to monitor the toxicity and efficacy at the specified interim analyses. The total expected sample sizes are 40.
Study: NCT03632577

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Oxygen (HFO)
Description: HFO is a mix tap of air and oxygen. It permits to control FiO2 and generated controlled high flow air until 60/min. Air and oxygen are mixed, warmed, humidified and issued to patient by a warming monopod inspiratory circuit to nasal cannulas of a large diameter. Expiration is free.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non Invasive Ventilation (NIV)
Description: NIV was already evaluated in post-extubation. This technic is now used in daily consolidation processing after extubation because it provides a ventilator help with two levels of pressure helping in respiratory work. Adding Automated Flow Oxygen Titration could optimized patient's oxygenation and reduce workload of caregivers.
Study: NCT04172922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Sirolimus
Description: Open label, topical sirolimus (1%) cream will be applied to cutaneous component of complicated vascular anomalies twice daily for 4 weeks and once daily thereafter- for the duration of study.
Study: NCT03634241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT04010864

Intervention type: OTHER
Intervention: routine clinical treatment
Description: Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
Study: NCT02380118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Intramuscular injection
Study: NCT01257412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg Oral dose od

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 5/10 mg Oral dose od
Study: NCT04358536

Intervention type: DEVICE
Intervention: CovX
Description: Convolutional neural network for classification of COVID-19 from chest X-rays

Intervention type: DEVICE
Intervention: CovX
Description: Convolutional neural network for classification of COVID-19 from chest X-rays
Study: NCT02740205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm for enteral nutrition support
Description: Enteral nutrition support prescribed by the Clinical Nutrition Service under the instructions of the algorithm based on evidence
Study: NCT04441827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing exercise
Description: Pranayama Group Breathing Exercises Step One:Focusing on breathing (1 minute) Step Two: Alternative nasal breathing (3 minutes) Step Three: Refreshing breath (3 minutes) Step Four: Humming bee breath (2 minutes) Step Five: Focusing on breathing (1 minute)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing exercise
Description: Pranayama Group Breathing Exercises Step One:Focusing on breathing (1 minute) Step Two: Alternative nasal breathing (3 minutes) Step Three: Refreshing breath (3 minutes) Step Four: Humming bee breath (2 minutes) Step Five: Focusing on breathing (1 minute)
Study: NCT02703753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: The investigational treatment consists of a lifestyle intervention targeting on a healthy diet, physical activity and, if applicable, smoking cessation.
Study: NCT04771962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DESFLURANE AND SEVOFLURANE
Description: COMPARING THE EFFICACY IN MAINTAINANCE OF SPONTANEOUS GENERAL ANAESTHESIA USING AMBU AURA GAIN IN PEDIATRIC PATIENTS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DESFLURANE AND SEVOFLURANE
Description: COMPARING THE EFFICACY IN MAINTAINANCE OF SPONTANEOUS GENERAL ANAESTHESIA USING AMBU AURA GAIN IN PEDIATRIC PATIENTS
Study: NCT02330562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRZ
Description: MRZ dosing in Phase 1 to range from 0.55 to 0.8 mg/m2. Dose Escalation: MRZ dose-escalation will occur using a standard 3+3 study design.~The RP2D of MRZ (0.8.mg/m2) will be used in a two stage design, with fifteen response-evaluable patients entered in the first stage. If 1 or more responses are observed at the MRZ RP2D, then the second stage will be implemented with an additional 15 response-evaluable patients treated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEV
Description: BEV 10 mg/kg IV infusion administered for all cohorts in Phase 1 only.
Study: NCT04214275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: Simple breathing techniques, secretion-removal techniques, airway-cleaning techniques, mobilization techniques and use of an incentive spirometer
Study: NCT01065207

Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: blood test at day one
Description: Epidemiological, clinical, virological, and immunological data will be collected.~Clinical events as neoplasia will be collected
Study: NCT01721174

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SEMS only
Description: The SEMS (Niti-S biliary uncovered metallic stent; Taewoong Medical, Korea) would be placed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EBRFA and SEMS
Description: The radiofrequency ablation (RFA) catheter would be placed under fluoroscopic guidance across the biliary stricture. The Habib EndoHPB (EMcision UK, London, United Kingdom) radiofrequency ablation catheter is a bipolar RFA probe that is 8F (2.6 mm), 1.8 m long, compatible with standard (3.2-mm working channel) side-viewing endoscopes, and passes over 0.035-inch guidewires. The catheter has 2 ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5-cm length. Depending on the length of the stricture, sequential applications would be applied to complete treatment throughout the length of the stricture without significant overlap of treated areas. An uncovered SEMSs (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea) would be placed after 2 sessions of EBRFA.
Study: NCT04150341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-8236
Description: The study drug will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-8236
Description: The study drug will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.
Study: NCT00946634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. After a last foaming with ozone gas (Philozon, Santa Catarina, Brazil) at 40mg/L concentration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control (no last irrigation)
Description: Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aqueous Ozone
Description: Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. A last irrigation with 10mL of ozonated water at 40mg/mL concentration
Study: NCT02674009

Intervention type: DRUG
Intervention: Vismodegib
Description: Participants with laBCC will receive a dosing of Vismodegib in accordance with local clinical practice and local labeling.
Study: NCT03972865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EmbrunMan race
Description: The EmbrunMan is a long-duration triathlon including 3.8 km of swimming, 188 km of cycling and 42.2 km of running, with a cumulative vertical drop of 4000 metres. Duration of the race varies between 10 hours and 16hours depending on the athletes' performance.
Study: NCT00405912

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (inactive drug) given 3 times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: St. John's Wort-900 mg/day
Description: St. John's Wort - 300 mg tables -3 times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: St. John's Wort-1800mg/day
Description: St. John's Wort - 600 mg tables - 3 times per day
Study: NCT02380118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Intramuscular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Intramuscular injection
Study: NCT02774005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone